van den Bosch R P, van der Schelling G P, Klinkenbijl J H, Mulder P G, van Blankenstein M, Jeekel J
Department of General Surgery, University Hospital Dijkzigt, The Netherlands.
Ann Surg. 1994 Jan;219(1):18-24. doi: 10.1097/00000658-199401000-00004.
This study was set up to identify patient-related factors favoring the application of either surgery or endoprostheses in the palliation of obstructive jaundice in subsets of patients with cancer of the head of the pancreas or periampullary region.
In the palliation of obstructive jaundice, surgical biliodigestive anastomosis has traditionally been performed. Surgical biliary bypass is associated with high mortality (15% to 30%) and morbidity rates (20% to 60%) but little recurrent obstructive jaundice (0% to 15%). Biliary drainage with endoscopically placed endoprostheses has a lower complication rate, but recurrent obstructive jaundice is seen in up to 20% to 50% of patients.
Patients with advanced cancer of the head of the pancreas or periampullary region treated at the University Hospital Dijkzigt, Rotterdam, The Netherlands, between 1980 and 1990 were reviewed. In 148 patients, data were compared concerning the morbidity and hospital stay after the palliation of obstructive jaundice with endoscopic endoprostheses or surgical biliary bypasses. These patients were stratified for long (> 6 months) and short (< 6 months) survival times.
In short-term survivors, the higher late morbidity rates after endoprostheses were offset by higher early morbidity rates and longer hospital stays after the surgical bypass. In long-term survivors, there was no difference in the hospital stay between the two groups, but the late morbidity rate was significantly higher in the endoprosthesis group.
These data suggest that endoscopic endoprosthesis is the optimal palliation for patients surviving less than 6 months and surgical biliary bypass for those surviving more than 6 months. This policy necessitates the development of prognostic criteria, which were obtained by Cox proportional-hazards survival analysis. Advanced age, male sex, liver metastases, and large diameters of tumors were unfavorable prognostic factors. With these factors, the risk of short- or long-term survival can be predicted. It is hoped that the application of these data may allow a rational approach toward optimal palliative treatment of this form of malignant obstructive jaundice.
本研究旨在确定在胰腺癌或壶腹周围区域癌患者亚组中,有利于应用手术或内置假体缓解梗阻性黄疸的患者相关因素。
在梗阻性黄疸的姑息治疗中,传统上采用外科胆肠吻合术。外科胆道旁路手术死亡率高(15%至30%)、发病率高(20%至60%),但复发性梗阻性黄疸发生率低(0%至15%)。内镜下放置内置假体进行胆道引流并发症发生率较低,但高达20%至50%的患者会出现复发性梗阻性黄疸。
回顾了1980年至1990年间在荷兰鹿特丹迪克齐格特大学医院接受治疗的晚期胰腺癌或壶腹周围区域癌患者。对148例患者在内镜下放置内置假体或外科胆道旁路缓解梗阻性黄疸后的发病率和住院时间数据进行了比较。这些患者按生存时间长(>6个月)和短(<6个月)进行分层。
在短期存活者中,内置假体术后较高的晚期发病率被外科旁路术后较高的早期发病率和较长的住院时间所抵消。在长期存活者中,两组的住院时间无差异,但内置假体组的晚期发病率显著更高。
这些数据表明,内镜下内置假体是生存期少于6个月患者的最佳姑息治疗方法,而外科胆道旁路则适用于生存期超过6个月的患者。该策略需要制定预后标准,通过Cox比例风险生存分析得出。高龄、男性、肝转移和肿瘤直径较大是不利的预后因素。有了这些因素,可以预测短期或长期生存的风险。希望这些数据的应用能够为这种恶性梗阻性黄疸的最佳姑息治疗提供合理的方法。